MK-801 differentially affects dopamine D1 and D2 receptor agonist- induced behavioral tolerance and desensitization

Brain Research

Volumn 725, Issue 1, 1996, Pages 67-74

  Asin, Karen E ^a   Bednarz, Lisa ^a   Nikkel, Arthur L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 85653; Dopamine; Fos; MK 801; Quinpirole; Rotation; Sensitization; Tolerance

Indexed keywords

DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CIRCLING BEHAVIOR; DESENSITIZATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG RECEPTOR BINDING; FOREBRAIN; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030600001     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00348-4     Document Type: Article

References (44)

1. [1] Asin, K.E. and Montana, W.E., Rotation following intranigral injections of a selective D1 or a selective D2 dopamine receptor agonist in rats, Pharmacol. Biochem. Behav., 29 (1988) 89-92.
2. [2] Asin, K.E., Bednarz, L. and Montana, W., Rotation in response to selective dopamine receptor agonists in rats with electrolytic substantia nigra lesions, Life Sci., 46 (1990) 1817-1823.
3. [3] Asin, K.E. and Wirtshafter, D., Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression, Eur. J. Pharmacol., 235 (1993) 167-168.
4. [4] Asin, K.E., Bednarz, L., Nikkel, A. and Perner, R., Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa, J. Pharmacol. Exp. Ther., 273 (1995) 1483-1490.
5. [5] Boldry, R.C., Chase, T.N. and Enger, T.M., Influence of previous exposure to L-dopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in 6-hydroxydopamine lesioned rats, J. Pharmacol. Exp. Ther.. 267 (1993) 1454-1459.
6. [6] Carter, C.J. Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats, Neuropharmacol., 21 (1982) 379-383.
7. [7] Cenci, M.A. and Bjorklund, A., Transection of corticostriatal afferents reduces amphetamine-and apomorphine-induced striatal Fos expression and turning behaviour in unilaterally 6-hydroxydopamine-lesioned rats, Eur. J. Neurosci., 5 (1993) 1062-1070.
8. [8] Clineschmidt, B.V., Martin, G.E., Bunting, P.R. and Papp, N.L., Central sympathornimetic activity of ( + )-5methy 1-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties, Drug Dev. Res., 2 (1982) 135-145.
9. [9] Engber, T.M., Anderson, J.J., Boldry, R.C., Kuo, S. and Chase, T.N., N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion, Neuroscience, 54 (1993) 1051-1061.
10. [10] Engber, T.M., Papa, S.M., Boldry, R.C. and Chase, T.N., NMDA receptor blockade reverses motor response alterations induced by levodopa, NeuroReport, 5 (1994) 2586-2588.
11. [11] Fenu, S., Cara, A. and Morelli, M., Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra, Synapse, 19 (1995) 233-240.
12. [12] Fu, L. and Beckstead, R.M., Cortical stimulation induces fos expression in striatal neurons, Neuroscience, 46 (1992) 329-334.
13. [13] Gancher, S. and Mayer, A., Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response, Brain Res., 682 (1995) 63-68.
14. [14] Gandolfi, O., Rimondini, R. and Dair'Olio, R., The modulation of dopaminergic transmission in the striatum by MK-801 is independent of presynaptic mechanisms, Neuropharmacology, 31 (1992) 1111-1114.
15. [15] Goodwin, P., Starr, B.S. and Starr, M.S., Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801, J. Neural Transm., 4 (1992) 15-26.
16. [16] Hiramatsu, M, Cho, A.K. and Nabeshima, T., Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-901 and phencyclidine, Eur. J. Pharmacol., 166 (1989) 359-366.
17. [17] Karler, R., Calder, L.D., Chaudhry, I.A. and Turkanis, S.A., Blockade of 'reverse tolerance' to cocaine and amphetamine by MK-801, Life Sci., 45 (1989) 599-606.
18. [18] Karler, R., Chaudhry, I.A., Calder, L.D. and Turkanis, S.A., Amphetamine behavioral sensitization and the excitatory amino acids, Brain Res., 537 (1990) 80-82.
19. [19] Karler, R., Calder, L.D. and Bedingfield, J.B., Cocaine behavioral sensitization and the excitatory amino acids, Psychopharmacology, (1994) 305-310.
20. [20] Kashihara, K., Hamarura, T., Okumura, K. and Otsuki, S., Effect of MK-801 on endogenous dopamine release in vivo, Brain Res., 528 (1990) 80-82.
21. [21] Kiss, J.P., Tóth, E., Lajtha, A. and Vizi, E.S., NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: a microdialysis study, Brain Res., 641 (1994) 145-148.
22. [22] LaHoste, G.J. and Marshall, J.F., Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists, Behav. Brain Res., 38 (1990) 232-242.
23. [23] Morelli, M. and Di Chiara, G., MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease, Eur. J Pharmacol., 182 (1990) 611-612.
24. [24] Morelli, M. and Di Chiara, G., Stereospecific blockade of N-methyl-D-aspartate transmission by MK-801 prevents priming of SKF 38393-induced turning, Psychopharmacology, 101 (1990)287-288.
25. [25] Morelli, M., Fenu, S. Pinna, A. and Di Chiara, G., Opposite effects of NMDA blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression, J. Pharmacol. Exp Ther., 290 (1992) 402-408.
26. [26] Morelli, M., Pinna, A., Fenu, S., Carta, A., Cozzolineo, A. and Di Chiara, G., Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats. Synapse. 18 (1994) 288-293.
27. [27] Ohno, M., Yoshida, H. and Watanabe, S., NMDA receptor-mediated expression of Fos protein in the rat striatum following methamphetamine administration: relation to behavioral sensitization, Brain Res., 665 (1994), 135-140.
28. [28] Paul, M.L., Currie, R.W. and Robertson, H.A., Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity, Neuroscience, 66 (1995) 347-359.
29. [29] Pinheiro-Carrera, M., Tomaz, C., Huston, J.P. and Carey, R.J., NMDA antagonist effects on the development of L-DOPA behavioral sensitization in rats, Behav. Neurosci., 109 (1995) 34-42.
30. [30] Shoaib, M. and Stolerman, I.P., MK-801 attenuates behavioural adaptation to chronic nicotine administration in rats, Br. J. Pharmacol., 105 (1992) 514-515.
31. [31] Starr, M.S., Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease, Synapse, 19 (1995) 264-293.
32. 2 agonist apomorphine. J. Neural Transm., 6 (1993) 215-226.
33. [33] Stewart, J. and Druhan, J.P., Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801, Psychopharmacology, 110 (1993) 125-132.
34. [34] St-Pierre, J.-A. and Bedard, P.J., Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model, Brain Res., 660 (1994) 255-260.
35. [35] St-Pierre, J.-A, and Bedard, P.J., Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine, Eur. J. Pharmacol., 272 (1995) 123-129.
36. [36] Svensson, A., Carlsson, M.L. and Carlsson, A., Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in the opposite directions depending on the dopaminergic tone, Prog. Neuro-Psychoph. Biol. Psychiat., 18 (1994) 1203-1218.
37. [37] Wedzony, K., Golembiowska and Klimek, V., MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex, Brain Res., 625 (1993) 333-336.
38. [38] Wedzony, K. and Czyrak, A., The role of corticosteroids in the acquisition of sensitization to locomotor stimulant effects of MK-801, Brain Res., 675 (1994) 351-356.
39. [39] Weihmuller, F.B., O'Dell, S.J., Cole, B.N. and Marshall, J.F., MK-801 attenuates the dopamine-releasing but not the behavioral effects of metamphetamine: an in vivo microdialysis study, Brain Res., 549 (1991) 230-235.
40. [40] Whitton, P.S., Biggs, C.S., Pearce, B.R. and Fowler, L.J., Regional effects of MK-801 on dopamine and its metabolites studied by in vivo microdialysis, Neurosci. Lett., 142 (1992) 5-8.
41. [41] Wolf, M.E. and Khansa, M.R., Repeated administration of MK-801 produces sensitization to its own locomotor stimulation effects but blocks sensitization to amphetamine, Brain Res., 562 (1991) 164-168.
42. [42] Wolf, M.E. and Jeziorski, M., Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization, Brain Res.. 613 (1993) 291-294.
43. [43] Wolf, M.E., White, F.J. and Hu, X.-T., Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system, Behav. Pharmacol., 4 (1993) 429-442.
44. [44] Wolf, M.E., Xue, C.-J., White, F.J. and Dahlin, S.L., MK-801 does not prevent acute stimulatory effects of amphetamine or cocaine on locomotor activity or extracellular dopamine levels in rat nucleus accumbens, Brain Res., 666 (1994) 223-231.